Kymera Therapeutics (KYMR) Competitors $40.66 +1.52 (+3.88%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KYMR vs. QGEN, ITCI, ROIV, ASND, RVMD, LNTH, NUVL, BPMC, LEGN, and ELANShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Blueprint Medicines (BPMC), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Blueprint Medicines Legend Biotech Elanco Animal Health Qiagen (NYSE:QGEN) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Which has more volatility and risk, QGEN or KYMR? Qiagen has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Does the media prefer QGEN or KYMR? In the previous week, Qiagen had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 5 mentions for Qiagen and 1 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.67 beat Qiagen's score of 0.47 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer QGEN or KYMR? Qiagen currently has a consensus target price of $51.88, suggesting a potential upside of 16.13%. Kymera Therapeutics has a consensus target price of $53.88, suggesting a potential upside of 32.52%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67Kymera Therapeutics 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has higher earnings and valuation, QGEN or KYMR? Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.97B5.18$341.30M$0.39114.54Kymera Therapeutics$87.56M30.07-$146.96M-$2.34-17.38 Does the MarketBeat Community believe in QGEN or KYMR? Qiagen received 196 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 60.88% of users gave Qiagen an outperform vote while only 52.48% of users gave Kymera Therapeutics an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.88% Underperform Votes16039.12% Kymera TherapeuticsOutperform Votes5352.48% Underperform Votes4847.52% Is QGEN or KYMR more profitable? Qiagen has a net margin of 4.73% compared to Kymera Therapeutics' net margin of -191.26%. Qiagen's return on equity of 13.43% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.73% 13.43% 8.10% Kymera Therapeutics -191.26%-24.96%-20.27% Do insiders & institutionals have more ownership in QGEN or KYMR? 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 15.8% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryQiagen beats Kymera Therapeutics on 11 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63B$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-17.3846.7389.8217.18Price / Sales30.07415.011,116.21116.95Price / CashN/A182.1042.8937.86Price / Book5.713.894.784.78Net Income-$146.96M-$42.21M$120.23M$225.60M7 Day Performance-3.49%-2.15%-1.92%-1.23%1 Month Performance-7.82%4.20%11.49%3.36%1 Year Performance60.71%18.39%30.57%16.60% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics2.27 of 5 stars$40.66+3.9%$53.88+32.5%+66.0%$2.63B$87.56M-17.38170QGENQiagen3.512 of 5 stars$45.41+0.0%$51.15+12.6%+3.1%$10.36B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0477 of 5 stars$84.71+2.0%$97.23+14.8%+27.8%$8.98B$612.78M-95.91560ROIVRoivant Sciences3.0007 of 5 stars$12.05+1.8%$17.93+48.8%+16.2%$8.77B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.1363 of 5 stars$134.92+3.9%$191.77+42.1%+12.6%$8.18B$327.43M-16.52640RVMDRevolution Medicines4.5486 of 5 stars$44.75-0.6%$63.67+42.3%+71.5%$7.53B$11.58M-12.54443Insider TradeLNTHLantheus4.3778 of 5 stars$94.39+1.5%$130.00+37.7%+53.4%$6.56B$1.50B15.42834Analyst ForecastNUVLNuvalent2.1944 of 5 stars$86.97+0.1%$112.60+29.5%+16.9%$6.18BN/A-25.0340Insider TradeNews CoveragePositive NewsBPMCBlueprint Medicines2.5701 of 5 stars$95.22+2.2%$122.11+28.2%+7.2%$6.05B$434.42M-45.28640Insider TradeLEGNLegend Biotech1.548 of 5 stars$32.85-6.5%$81.54+148.2%-43.2%$6.00B$520.18M-36.971,800ELANElanco Animal Health3.7792 of 5 stars$12.13+0.2%$16.75+38.1%-17.0%$6.00B$4.45B30.259,300 Related Companies and Tools Related Companies QGEN Competitors ITCI Competitors ROIV Competitors ASND Competitors RVMD Competitors LNTH Competitors NUVL Competitors BPMC Competitors LEGN Competitors ELAN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KYMR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
